Lauren Abbott
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.4% of the total across 287 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 41 manufacturers reported payments, led by AbbVie at 29.7% of the total. Reporting peaked in 2024 at $3,149 and has fallen 57.8% since, to $1,330 in 2025. Among family clinicians in NH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 287 payments — averaging $20.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Lundbeck LLC$441
- Teva Pharmaceuticals USA, Inc.$429
- Pfizer$345
- Jazz Pharmaceuticals Inc.$313
- UCB, Inc.$173
- plus $2K from 35 others
What the payments were for
- Food & beverage$5,71597%
- Education$1553%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$5,870 in reported general payments places this provider in the 95th percentile of 713 family providers in New Hampshire.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Nurtec OdtRimegepant Sulfate | 27 | $35,240 |
| QuliptaAtogepant | 13 | $13,940 |
| Emgality PenGalcanezumab-Gnlm | 13 | $8,305 |
| Pregabalin | 44 | $1,421 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 33 | $910 |
| Modafinil | 13 | $450 |
| Gabapentin | 21 | $305 |
| Clonazepam | 13 | $85 |
| Prednisone | 17 | $59 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerNurtec Odt | $345 | $35,24027 claims |
| AbbVieQulipta | $1,744 | $13,94013 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 713 family providers in New Hampshire.
Other family in Derry
- Summer BellDerry$16K
- Allison AnastasoffDerry$4K
- Jan LevesqueDerry$3K
- Jenna ClarkDerry$3K
- Tara Delle ChiaieHampton$548K
- Wendy WrightAmherst$447K
- Richard CareyNashua$51K
- Laura HudsonDover$14K
- Debra KrisonNorth Hampton$13K
- Michelle WhiteBedford$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.